Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 NDC API, 2 Listed Suppliers

2 API Suppliers
1 NDC API
2 Listed Suppliers

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 28 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
28 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 Annual Reports

globalSalesInformation
1 Annual Reports

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cyt387, 1056634-68-4, Cyt-387, Cyt 387, N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, Cyt 11387

Molecular Formula

C₂₃H₂₂N₆O₂

Molecular Weight

414.5 g/mol

InChI Key

ZVHNDZWQTBEVRY-UHFFFAOYSA-N

FDA UNII

6O01GMS00P

Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.

1 2D Structure

Momelotinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

2.1.2 InChI

InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)

2.1.3 InChI Key

ZVHNDZWQTBEVRY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N

2.2 Other Identifiers

2.2.1 UNII

6O01GMS00P

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cyt 387

2. Cyt-387

3. Cyt387

4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

2.3.2 Depositor-Supplied Synonyms

1. Cyt387

2. 1056634-68-4

3. Cyt-387

4. Cyt 387

5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide

6. Cyt 11387

7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

8. Gs-0387

9. Momelotinib (cyt387)

10. Cyt-11387

11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide

12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

14. 6o01gms00p

15. Chembl1078178

16. Cyt-0387

17. Cyt11387

18. Mfcd16038899

19. Lm-1149

20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide

21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide

22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-

23. Momelotinib [usan]

24. Momelotinib [usan:inn]

25. Momelotinibum

26. Unii-6o01gms00p

27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

28. C87

29. Momelotinib [inn]

30. Momelotinib (usan/inn)

31. Momelotinib [who-dd]

32. Mls006011154

33. Gtpl7791

34. Schembl2237234

35. Chebi:91407

36. Ex-a260

37. Dtxsid801026049

38. Hms3244k19

39. Hms3244k20

40. Hms3244l19

41. Hms3295i01

42. Hms3655d12

43. Hms3744c15

44. Bcp02328

45. Cyt387, Cyt11387

46. Cyt387,cyt 11387

47. Momelotinib (cyt387,cyt-387)

48. Bdbm50311017

49. Nsc767598

50. Nsc800800

51. S2219

52. Zinc43199890

53. Akos015904624

54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide

55. Bcp9000570

56. Ccg-264946

57. Cs-0053

58. Db11763

59. Nsc-767598

60. Nsc-800800

61. Sb14602

62. Ncgc00244257-01

63. Ncgc00244257-08

64. Ac-23162

65. As-19389

66. Hy-10961

67. Smr004702928

68. Sy060668

69. Ft-0755949

70. Sw219679-1

71. D10315

72. A857769

73. Q252602

74. J-001468

75. J-523159

76. Brd-k87737963-001-01-1

77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide

78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide

80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387

83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

2.4 Create Date

2008-12-01

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₂N₆O₂
Molecular Weight	414.5 g/mol
XLogP3	2.6
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Exact Mass	414.18042397 g/mol
Monoisotopic Mass	414.18042397 g/mol
Topological Polar Surface Area	103 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	615
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of myelofibrosis

Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

API SUPPLIERS